Lestaurtinib(CAS: 111358-88-4)

Lestaurtinib (CAS: 111358-88-4) is an orally active tyrosine kinase inhibitor used primarily in the treatment of certain types of leukemia, specifically in the therapy of T-cell acute lymphoblastic leukemia (T-ALL) and to some extent, T-cell prolymphocytic leukemia (T-PLL).

Lestaurtinib (CAS: 111358-88-4) is mainly used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell prolymphocytic leukemia (T-PLL). It inhibits multiple tyrosine kinases, including Lck, to block signal transduction pathways involved in the proliferation of T-cell acute leukemia cells.

Lestaurtinib (CAS: 111358-88-4) is generally considered safe when used under medical supervision. However, it can cause side effects such as nausea, vomiting, and diarrhea. Patients should follow prescribed dosages and medical advice to minimize risks.

Lestaurtinib (CAS: 111358-88-4) should be stored at room temperature, between 15°C to 30°C (59°F to 86°F), and should be kept in a tightly closed container, away from direct light and moisture. Avoid storing it in humid or high-temperature environments to maintain its efficacy and stability.